AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders
- 9 June 2010
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 150 (1), 46-57
- https://doi.org/10.1111/j.1365-2141.2010.08175.x
Abstract
P>Constitutive activation of Janus kinase (Jak) 2 is the most prevalent pathogenic event observed in the myeloproliferative disorders (MPD), suggesting that inhibitors of Jak2 may prove valuable in their management. Inhibition of the Aurora kinases has also proven to be an effective therapeutic strategy in a number of haematological malignancies. AT9283 is a multi-targeted kinase inhibitor with potent activity against Jak2 and Aurora kinases A and B, and is currently being evaluated in clinical trials. To investigate the therapeutic potential of AT9283 in the MPD we studied its activity in a number of Jak2-dependent systems. AT9283 potently inhibited proliferation and Jak2-related signalling in Jak2-dependent cell lines as well as inhibiting the formation of erythroid colonies from haematopoietic progenitors isolated from MPD patients with Jak2 mutations. The compound also demonstrated significant therapeutic potential in vivo in an ETV6-JAK2 (TEL-JAK2) murine leukaemia model. Inhibition of both Jak2 and Aurora B was observed in the model systems used, indicating a dual mechanism of action. Our results suggest that AT9283 may be a valuable therapy in patients with MPD and that the dual inhibition of Jak2 and the Aurora kinases may potentially offer combinatorial efficacy in the treatment of these diseases.Keywords
This publication has 45 references indexed in Scilit:
- Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283Cell Cycle, 2009
- Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndromeThe Lancet, 2008
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortBlood, 2008
- PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerMolecular Cancer Therapeutics, 2007
- The Myeloproliferative DisordersThe New England Journal of Medicine, 2006
- Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeThe New England Journal of Medicine, 2003
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaThe New England Journal of Medicine, 2002
- Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the DiseaseThe New England Journal of Medicine, 1976